| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
3)-ß-D-Glucan from Alcaligenes faecalis var. myxogenes, IFO 13140, and Its Acid-degraded Products1
Chemotherapy Division, National Cancer Center Research Institute, Tsukiji 5-chome, Chuo-ku, Tokyo, Japan 104
The well-defined (1
3)-ß-D-glucan with
540, produced by cultivation of Alcaligenes faecalis var. myxogenes (IFO 13140), a mutant of a soil bacterium, had marked inhibitory activity against the s.c.-implanted Sarcoma 180 at 5 to 50 mg/kg for 10 days. It also exhibited very high activity in doses of 60 and 100 mg/kg i.p. by a single injection at 7 days after the initial s.c. transplantation of Sarcoma 180. The inhibition ratios observed with Ehrlich carcinoma, NTF (Nakahara-Tokuzen-Fukuoka) reticulum cell sarcoma, and CCM adenocarcinoma were somewhat less but were still significant. On the other hand the treatment failed to inhibit the growth of ascites Sarcoma 180 or to induce prolongation of life span. The mechanism of action of this glucan was considered to be host mediated because of a lack of effect in vitro and also because of the effectiveness of pretreatment of animals by injection before transplantation of a tumor. The results from the bioassay study of the lower-molecular-weight (1
3)-ß-D-glucans prepared from the glucan with number-average degrees of polymerization
540 by hydrolysis with formic acid or sulfuric acid showed that the glucans with
inhibited the growth of Sarcoma 180 implanted s.c. in mice, whereas the result of the schedule-dependent effect was obtained in the pretreatment of animals by the glucan with
50. By i.v. administration, even the glucan with
16 showed a strong antitumor effect comparable to that of the glucan with
540.
1 This work was supported in part by Grants-in-Aid for Cancer Research from both the Ministry of Health and Welfare and the Ministry of Education, Science and Culture, Japan.
2 To whom requests for reprints should be addressed, at Section of Experimental Chemotherapy, Division of Chemotherapy, National Cancer Center Research Institute, Tsukiji 5-chome, Chuo-ku, Tokyo, Japan 104.
3 Permanent address: Central Research Division, Takeda Chemical Industries, Ltd., Osaka, Japan.
Received 7/ 8/77. Accepted 11/11/77.
This article has been cited by other articles:
![]() |
K. Kataoka, T. Muta, S. Yamazaki, and K. Takeshige Activation of Macrophages by Linear (1right-arrow3)-beta -D-Glucans. IMPLICATIONS FOR THE RECOGNITION OF FUNGI BY INNATE IMMUNITY J. Biol. Chem., September 20, 2002; 277(39): 36825 - 36831. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |